Insmed (INSM) is seeing favorable physician feedback on its Brinsupri therapy, with doctors liking the drug's profile and expecting to increase use in the near and long term, RBC Capital Markets said in a Tuesday note.
Brinsupri is a prescription drug developed by Insmed to treat non-cystic fibrosis bronchiectasis.
A survey of 50 physicians showed respondents viewed the drug favorably and said the potentially eligible patient population could expand over time, according to the note.
The survey suggested the bronchiectasis market is dominated by moderate and high prescribers, which could support early launch momentum, RBC said.
Additionally, the firm noted payer dynamics appeared manageable, with denials not a major obstacle for most physicians surveyed.
Brinsupri is expected to generate about $1.35 billion in sales in 2026, including roughly $201.3 million in Q1, according to RBC.
RBC maintained its outperform rating on Insmed and raised its price target to $216 from $212.
Price: $152.47, Change: $+1.33, Percent Change: +0.88%